Physician profile
Jun Lu
NPI 1043403371
$4,087.02
in general payments reported to CMS, 2019-2025
23 companies · $846 in 2025
The $846 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $859 · 2020: $250 · 2021: $198 · 2022: $318 · 2023: $881 · 2024: $735 · 2025: $846.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,347 · Education: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,346.92 |
| Education | $115.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $720.86 | 2019-2024 | Tremfya |
| Astrazeneca Pharmaceuticals Lp | $623.78 | 2019-2025 | Airsupra, Tezspire |
| Biocryst US Sales Co., LLC | $409.79 | 2021-2025 | Orladeyo |
| Regeneron Healthcare Solutions, INC. | $346.74 | 2019-2025 | Dupixent |
| Genzyme Corporation | $263.01 | 2019-2025 | |
| Glaxosmithkline, LLC. | $232.43 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $231.48 | 2019-2025 | Xolair |
| Ars Pharmaceuticals Operations, INC. | $193.47 | 2025 | Neffy |
| Celgene Corporation | $160.61 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $115.24 | 2022-2024 | Eohilia |
| Aimmune Therapeutics, INC. | $112.87 | 2022 | |
| Conmed Corporation | $104.13 | 2020 | |
| Sanofi-Aventis U.S. LLC | $99.99 | 2025 | |
| Abbvie INC. | $83.79 | 2022 | |
| Kaleo, INC. | $71.81 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $68.06 | 2019-2024 | Actimmune, Tezspire |
| Genentech USA, INC. | $67.93 | 2024-2025 | Xolair |
| Pfizer INC. | $66.51 | 2019-2023 | |
| Horizon Therapeutics Plc | $42.25 | 2021-2023 | Actimmune |
| Incyte Corporation | $24.22 | 2025 | Opzelura |
| Teva Pharmaceuticals USA, INC. | $18.13 | 2019 | |
| Greer Laboratories, INC. | $16.76 | 2025 | Oralair |
| Alk-Abello, INC | $13.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jun Lu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.